Canada Life’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Canada Life’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,026	Closed	-$5K	–	2311
2023 Q1	$5K	Hold	2,026	–	–	﹤0.01%	2310
2022 Q4	$11K	Buy	+2,026	New	+$17K	﹤0.01%	2320
2022 Q2	–	Sell	-2,277	Closed	-$18K	–	2475
2022 Q1	$18K	Hold	2,277	–	–	﹤0.01%	2378
2021 Q4	$23K	Hold	2,277	–	–	﹤0.01%	2353
2021 Q3	$31K	Hold	2,277	–	–	﹤0.01%	2356
2021 Q2	$50K	Hold	2,277	–	–	﹤0.01%	2274
2021 Q1	$54K	Hold	2,277	–	–	﹤0.01%	2268
2020 Q4	$41K	Hold	2,277	–	–	﹤0.01%	2355
2020 Q3	$26K	Hold	2,277	–	–	﹤0.01%	2380
2020 Q2	$55K	Hold	2,277	–	–	﹤0.01%	2199
2020 Q1	$25K	Hold	2,277	–	–	﹤0.01%	2334
2019 Q4	$60K	Buy	+2,277	New	+$53.3K	﹤0.01%	2206
2019 Q3	–	Sell	-2,612	Closed	-$80K	–	2380
2019 Q2	$80K	Hold	2,612	–	–	﹤0.01%	2295
2019 Q1	$43K	Hold	2,612	–	–	﹤0.01%	2291
2018 Q4	$48K	Hold	2,612	–	–	﹤0.01%	2389
2018 Q3	$137K	Hold	2,612	–	–	﹤0.01%	2098
2018 Q2	$113K	Buy	2,612 +1,560	+148%	+$66.8K	﹤0.01%	2150
2018 Q1	$39K	Hold	1,052	–	–	﹤0.01%	2416
2017 Q4	$21K	Buy	+1,052	New	+$22.6K	﹤0.01%	2498

Other funds holding GTHX

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Canada Life's GTHX Position: Q2 2023 in Review

Canada Life sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2023, closing a stake of 2,026 shares — an estimated $5K sold.

Canada Life first reported a position in GTHX in Q4 2017 and held it in 19 quarters. The position peaked at $137K in Q3 2018. 80 funds tracked by Wall St. Rank hold GTHX as of Q2 2023.

Canada Life reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Canada Life sold 2,026 G1 Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $5K.
Canada Life first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2017 and held it in 19 quarters.
Canada Life's G1 Therapeutics, Inc. Common Stock position peaked at $137K in Q3 2018.
80 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Canada Life's 13F filing for Q2 2023, filed 10 Aug 2023.